RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will participate in the Stifel 2026 Virtual Cardiometabolic Forum on Sept. 30, giving investors an opportunity to hear from management as the company develops lorundrostat for hypertension and related conditions.
Management is scheduled to participate in a fireside chat beginning at noon ET.
A live webcast will be available through the News & Events page of the Investor Relations section of the Mineralys Therapeutics website.
Mineralys is developing medicines targeting hypertension and related conditions associated with dysregulated aldosterone, including chronic kidney disease and obstructive sleep apnea.
Its lead product candidate, lorundrostat, is an investigational, orally administered aldosterone synthase inhibitor.
Mineralys is based in Radnor and was founded by Catalys Pacific. More information is available at https://mineralystx.com.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.